Treatments for patients that currently take place in the hospital can increasingly take place at home. Hospital-relocated care has both advantages and disadvantages. Patients, care providers and health insurers will have to work together to determine the definitive design of MSVT. Fagron is happy to think along with you about how this can be set up.

This module will help you with: 

• The MSVT module covers the content components in the current situation:
• What is MSVT really, what is it not and what is meant by low-complexity and high-complexity care?
• What does the MSVT routing process look like?
• Knowledge regarding which Fagron medication and service belong to MSVT
• What does the reimbursement look like regarding MSVT, how best to deal with rejected declarations, how can a structurally better reimbursement be obtained?
• What changes are taking place regarding MSVT?
• Where does medication for MSVT come from?
  
  

Join our events

Send us an email to enrole, request more information or share your suggestions.